| |  |
CordenPharma is your full-service CDMO in the manufacturing of innovative APIs, Lipid Excipients and Drug Products. Through a network of facilities organized under five technology platforms - Peptides - Lipids & Carbohydrates - Injectables - Highly Potent & Oncology - Small Molecules - CordenPharma experts translate complex ideas into high-value products.Peptides - World-class development & manufacturing services seamlessly supporting all clinical & commercial stages
- Fully-integrated solution from drug substance to fill & finish drug product
- Unique expertise in both SPPS & LPPS technology for efficient Peptide manufacturing
- Full access to batch record process (you own the IP) and knowledge sharing guaranteed
- Largest equipment available to leverage sizeable up and downstream processes for your APIs
- Solvent recycling concepts with a green manufacturing approach
Lipids & Carbohydrates - Specialized Lipids offering including custom & standard lipids (Glycero-Phospholipids, Sphingolipids, Phosphocholine, Pegylated, and Cationic Lipids)
- Lipids for support of mRNA vaccine production including Phosphocholine, Pegylated, Cationic Lipids and highly pure plant-based CP BotaniChol® (cholesterol)
- Fully-integrated service offering > from APIs to finished dosage and pharmaceutical services (clinical trial kits preparation, randomization and logistics)
- Backward integration of key starting materials to secure supply chain
- Manufacturing of carbohydrate-based APIs, vaccines, delivery systems, and conjugates (with lipids and/or peptides for receptor targeting)
Sterile Injectables - Wide & balanced range of injectable services (including combining injectable drugs & devices as combination products)
- Aseptic & Terminal Sterilization Fill & Finish Technologies for Pre-Filled Syringes (PFS), ampoules, liquid and lyophilized vials, supporting a wide range of filling volumes
- Substantial Drug Product regulatory and filing experience globally (EMEA, FDA, PMDA)
- Packaging / labeling Clinical trial drug kit management (logistics, track & trace, documentation)
- LNP Formulation of Drug Products
Highly Potent & Oncology Small Molecules - Integrated network of cGMP facilities across Europe and US
- 1,200 m3 of volumetric capacity in 20 L - 28,000 L reactors with various materials of construction
- Clinical (Phase I-III) and ongoing commercial supply to multiple markets around the world (including US, Europe and Japan)
- Kilo to Multi-ton production volumes per annum
- Process development capabilities (including flow / continuous manufacturing
- All sites FDA & EMEA approved facilities with successful regulatory & customer audits
- Strong EHS programs in place at sites
|
Product List: 49
PON:Page:
|
| |
2-Lyso-phospholipids | P-LYSO-PC CAS:17364-16-8 LP-R4-078 | S-LYSO-PC CAS:19420-57-6 LP-R4-083 |
Cationic & Ionizable Lipids | C12-200 CAS:1220890-25-4 LP-04-425 | DLIN-KC2-DMA CAS:119-0197-97-7 LP-04-242 | DODMA CAS:104162-47-2 LP-R4-110 | DOTAP CL CAS:132172-61-3 LP-R4-117 | DOTMA CAS:104162-48-3 LP-04-496 |
Cholesterol & Derivatives | BHEM-Chol CAS:624742-83-2 LP-04-492 | BotaniChol® (Cholesterol from plant origin) CAS:57-88-5 LP-C4-477 | CHEMS CAS:1510-21-0 LP-04-247 | Cholesterol-PEG CAS:205743-50-6 LP-04-493 | DC-CHOLESTEROL CAS:137056-72-5 LP-04-491 | MOCHOL CAS:452323-21-6 LP-04-248 | SCS (HIGH PURITY >98%) CAS:2864-50-8 LP-R4-091 |
MPEGylated (Methoxypolyethyleneglycol-) Phospholipids | mPEG-2000-DMPE, Na CAS:384835-59-0 LP-R4-123 | mPEG-2000-DPPE, Na CAS:205494-72-0 LP-R4-080 | mPEG-2000-DSPE, Na CAS:147867-65-0 LP-R4-039 | mPEG-5000-DMPE, Na CAS:384835-59-0 LP-R4-077 | mPEG-5000-DPPE, Na CAS:205494-72-0 LP-R4-075 | mPEG-5000-DSPE, Na CAS:147867-65-0 LP-R4-092 | mPEG-750-DSPE, Na CAS:147867-65-0 LP-R4-087 |
Phosphatidic Acids | DLPA, NA CAS:108321-06-8 LP-R4-121 | DMPA, NA CAS:80724-31-8 LP-R4-024 | DPPA, NA CAS:169051-60-9 LP-R4-025 | DSPA, NA CAS:108321-18-2 LP-R4-026 |
Phosphocholines | DLPC CAS:18194-25-7 LP-R4-101 | DMPC CAS:18194-24-6 LP-R4-058 | DOPC CAS:4235-95-4 LP-R4-070 | DPEPC, CHLORIDE CAS:328250-18-6 LP-R4-095 | DPEPC, TRIFLATE CAS:474945-32-9 LP-R4-102 | DPPC CAS:63-89-8 LP-R4-057 | DSPC CAS:816-94-4 LP-R4-076 |
Phosphoethanolamines | 1,2-POPE CAS:26662-94-2 LP-R4-266 | 1,3-DPPE CAS:67303-93-9 LP-R4-167 | DLPE CAS:42436-56-6 LP-R4-064 | DMPE CAS:998-07-2 LP-R4-018 | DOPE CAS:4004-05-01 LP-R4-069 | DPPE CAS:923-61-5 LP-R4-019 | DPYPE CAS:201036-16-0 LP-R4-147 | DSPE CAS:1069-79-0 LP-R4-020 |
Phosphoglycerols | DLPG, NA CAS:73548-69-3 LP-R4-079 | DMPG, NA CAS:200880-40-6 LP-R4- 015 | DPPG, NA CAS:200880-41-7 LP-R4-016 | DSPG, NA CAS:124011-52-5 LP-R4-017 | POPG, NA CAS:268550-95-4 LP-R4-124 | POPG, NH4 CAS:267228-70-6 LP-R4-074 |
Phospholipids | 1,3-POPE CAS:884324-34-9 LP-R4-163 | POPC CAS:26853-31-6 LP-R4-031 | SMPC CAS:20664-02-2 LP-R4-152 |
|
|
|